Back to Top

Annemieke DeMaggio's blog

A how-to on positioning yet another EGFR TKI (#6) for success

With already five EGFR TKIs to choose from, is there room for one more? Janssen thinks there is, betting on a combination strategy to defeat osimertinib

Accelerated FDA approval for pralsetinib in RET-fusion positive NSCLC

Approval based on the NSCLC cohorts included in the ARROW phase 1/2 study. Data from thyroid cancer cohorts has been filed; PDUFA in February 2021


Subscribe to RSS - Annemieke DeMaggio's blog